Best of ASCO - 2014 Annual Meeting

 

Welcome

Triple-Negative

Breast Cancer—Metastatic

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).

Romualdo Barroso-Sousa

TPS1119

A phase II, single arm study assessing the efficacy of pembrolizumab (Pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC).

Heather L. McArthur

1017

A randomized phase II trial of carboplatin with or without nivolumab in first- or second-line metastatic TNBC.

Ana Christina Garrido-Castro

TPS1118

A retrospective study of curcumin in combination with intravenous vitamin C (IVC) on triple negative breast cancer(TNBC).

Junwen Ou

e13118

Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.

Marleen Kok

1012

An open label, pilot study of veliparib (ABT-888) and lapatinib in patients with metastatic, triple negative (ER, PR, and HER-2 negative) breast cancer.

Erica Michelle Stringer-Reasor

1095

An open label, single arm, prospective phase II study to evaluate the efficacy and safety of bevacizumab with gemcitabine and carboplatin as first-line treatment for metastatic triple negative breast cancer patients.

Sudeep Gupta

1098

An orally available tubulin inhibitor, VERU-111, to overcome paclitaxel resistance and to suppress breast cancer tumor growth and metastasis.

Shanshan Deng

e13110

AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

Peter Schmid

1007

Biologic diversity of breast cancers in women with African ancestry.

Evelyn Mawunyo Jiagge

e13114

BRCA1 subcellular localization regulated by PI3K signaling pathway in triple negative breast cancer MDA-MB-231 cells and hormone-sensitve T47D cells.

Gang Sun

e13115

Characterization of the inflammatory infiltrate and association with expression of PD-1, PDL1 and PDL2 and survival in triple-negative mammary carcinoma.

Monique Celeste Tavares

1099

Circulating exosomal microRNA profiling to depict mechanisms of chemotherapy resistance among triple negative breast cancer.

Jianhua Zhao

e13124

Clinical profile of triple negative breast cancer in Indian women: Long term follow-up study.

Tara Rajendran

e13109

Development of targeted radiotherapy for triple negative breast cancer.

Shu-ta Wu

e13112

Elderly triple negative breast cancer patients: 15 years` Peruvian experience.

Gabriel Antonio De la Cruz Ku

e13129

Immune checkpoint marker expression and clinicopathological factors in primary TNBC.

Mascha Pervan

e13119

IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).

Rebecca Dent

TPS1115

IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC).

Rebecca Dent

TPS1117

Mechanisms of immune evasion in triple-negative breast cancer patients.

Javier Ignacio Orozco

1096

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).

Rebecca Dent

1008

Patterns of recurrence in triple negative breast cancer patients (automated IHC) : An Indian Tertiary Care Center data.

Joydeep Ghosh

e13128

Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).

Zachary William Neil Veitch

1094

Post-recurrence survival in triple negative breast cancer.

Zaida Morante

e13120

Preliminary report of a phase 1b/2a trial, an oral inhibitor of phosphorylated P68 (P-p68) which mediates β-catenin nuclear translocation in advanced triple-negative breast cancer (TNBC).

Jennifer Robinson Diamond

1097

Prognostic impact of age at diagnosis in triple negative breast cancer: Analysis of 204 patients from single institution registry.

Salman Otoukesh

e13130

Rational drug combination therapy for improved efficacy and delayed resistance in triple negative breast cancer.

Rabia Gilani

e13113

Survival of metastatic metaplastic breast cancer patients receiving chemotherapy.

Sparsha Kukunoor

e13126

Targeting mutant p53 with COTI-2: A new approach for the treatment of patients with triple-negative breast cancer?

Naoise C Synnott

e13121

TGF-beta/AURKA pharmacologic targeting to halt stemness and TNBC progression.

Antonino BONAVENTURA D'Assoro

e13127

TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.

Shaveta Vinayak

1011

Tumor mutation burden in triple negative breast cancer patients in Japan.

Masayuki Nagahashi

e13111

Understanding real-world treatment and outcomes in patients diagnosed with metastatic triple negative breast cancer (mTNBC).

Karen E Skinner

e13116

Updated survival data and biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.

Jian Zhang

1093

Vinorelbine plus capecitabine in a heavily pretreated HER2 negative metastatic breast cancer patient population: MCEPASTEBIN.

Alfredo Enrique Torres

e13122

VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes.

Andrew Tutt

TPS1116